GlassScriptPhysician profile
Jeffrey Edelman
NPI 1457476921
$53,390.78
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,236 · 2022: $1,383 · 2023: $143 · 2024: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $50K · Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $50,473.00 |
| Food and Beverage | $298.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $50,571.91 | 2021-2024 | Neurostar Tms Therapy System |
| Tris Pharma INC | $757.43 | 2021-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $425.71 | 2021-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $309.18 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $298.49 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $287.36 | 2021-2022 | |
| Corium, LLC | $235.13 | 2021-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $176.47 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $126.74 | 2021-2022 | |
| Abbvie INC. | $60.10 | 2021 | |
| Neurocrine Biosciences, INC. | $45.50 | 2022 | |
| Lundbeck LLC | $38.80 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $20.33 | 2022 | |
| Avanir Pharmaceuticals, INC. | $19.55 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Edelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.